Abstract
Nebulised colistin is regularly used as antipseudomonal therapy in children with cystic fibrosis. We assessed bronchoconstriction in response to nebulised colistin in 58 children. Nebulised colistin significantly reduced FEV1, MEF25%, and SaO2 for 15 minutes. In 20 children the reduction was greater than 10% from baseline FEV1, and was still at that level in five at 30 minutes. Subjective assessment, baseline FEV1, and serum IgE were unable to identify susceptible children. It is recommended that children receiving colistin should be carefully assessed for bronchoconstriction.
Full Text
The Full Text of this article is available as a PDF (76.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Chua H. L., Collis G. G., Le Souëf P. N. Bronchial response to nebulized antibiotics in children with cystic fibrosis. Eur Respir J. 1990 Nov;3(10):1114–1116. [PubMed] [Google Scholar]
- Dodd M. E., Abbott J., Maddison J., Moorcroft A. J., Webb A. K. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax. 1997 Jul;52(7):656–658. doi: 10.1136/thx.52.7.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mukhopadhyay S., Singh M., Cater J. I., Ogston S., Franklin M., Olver R. E. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax. 1996 Apr;51(4):364–368. doi: 10.1136/thx.51.4.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Polgar G., Weng T. R. The functional development of the respiratory system from the period of gestation to adulthood. Am Rev Respir Dis. 1979 Sep;120(3):625–695. doi: 10.1164/arrd.1979.120.3.625. [DOI] [PubMed] [Google Scholar]
- Ramagopal M., Lands L. C. Inhaled tobramycin and bronchial hyperactivity in cystic fibrosis. Pediatr Pulmonol. 2000 May;29(5):366–370. doi: 10.1002/(sici)1099-0496(200005)29:5<366::aid-ppul5>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
- Ramsey B. W., Pepe M. S., Quan J. M., Otto K. L., Montgomery A. B., Williams-Warren J., Vasiljev-K M., Borowitz D., Bowman C. M., Marshall B. C. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999 Jan 7;340(1):23–30. doi: 10.1056/NEJM199901073400104. [DOI] [PubMed] [Google Scholar]